- Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drugThe second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts. Smaller biotechs are increasingly opting to launch their pr…
- Visa time limits on foreign Ph.D. students and postdocs will harm U.S. science, experts warnA Trump administration plan to limit visas for graduate student and postdocs to four years is fueling concerns that the U.S. could lose out on foreign scientists